Oncology

All Items

• SyMMphony - From transplant-eligible newly diagnosed multiple myeloma to second-line CAR-T cell therapy: harmonizing treatment pathways to improve care

  Raffaela Giachero, Cirino Botta, Stefania Bramanti, Gabriele Buda, Tommaso Caravita di Toritto, Michele Cea, Giusy Cetani, Matteo Claudio Da Vià, Mattia d'Agostino, Danilo de Novellis, Roberta Della Pepa, Daniele Derudas, Anna Furlan, Barbara Gamberi, Luisa Giaccone, Giovanni Grillo, Carmine Liberatore, Katia Mancuso, Silvia Mangiacavalli, Giampaolo Marcacci, Massimo Martino, Anna Mele, Giuseppe Mele, Massimo Offidani, Laura Paris, Francesca Patriarca, Maria Teresa Petrucci, Stefano Rocco, Alessandra Romano, Elena Rossi, Bernardo Rossini, Renato Scalone, Simona Sica, Martina Tinelli, Renato Zambello, Claudia Yvonne Finocchiaro

  31-41

  DOI: https://doi.org/10.33393/ao.2026.3728

• Management of refractory metastatic colorectal cancer: consensus recommendations from Italian oncologists

  Fortunato Ciardiello, Carmine Pinto, Salvatore Siena, Alberto Sobrero, Marianna Morani

  7-12

  DOI: https://doi.org/10.33393/ao.2026.3578

• Follow-up of breast cancer: why is it necessary to start a Consensus in 2024?

  Stefania Gori, Alberto Zambelli, Catia Angiolini, Antonella Ferro, Fiorenza De Rose, Alessandra Fabi, Giuseppe Azzarello, Giuseppe Bogina, Maurizio Cancian, Matteo Valerio, Michela Cinquini, Fabrizio Nicolis, Giovanni Pappagallo

  10-17

  DOI: https://doi.org/10.33393/ao.2024.2634

• Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy

  Francesca Fiorentino, Beatrice Canali, Paolo Morelli, Federica Demma

  6-12

  DOI: https://doi.org/10.33393/ao.2023.2486

• Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test

  Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri

  105-111

  DOI: https://doi.org/10.33393/ao.2022.2447

• Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy

  Gian Luca Breschi, Federica Demma, Paolo Morelli, Maria De Francesco

  81-87

  DOI: https://doi.org/10.33393/ao.2021.2263

• The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

  Claudio Jommi, Roberto Ravasio

  78-85

  DOI: https://doi.org/10.33393/abtpn.2019.302

• Performance indicators for monitoring the integrated care pathway of patients with colorectal cancer: the E.Pic.A. project Performance indicators for colorectal cancer

  Andrea Ricotti, Giovanni Messori Ioli, Mattia Altini, Letizia Bachini, William Balzi, Giovanni Luca Frassineti, Fabrizio Gemmi, Ilaria Massa, Andrea Pierini, Oscar Bertetto, Patrizia Racca

  48-54

  DOI: https://doi.org/10.33393/abtpn.2019.292

• Key performance indicators for monitoring the integrated care pathway in breast cancer: the E.Pic.A. project

  Mattia Altini, William Balzi, Roberta Maltoni, Fabio Falcini, Flavia Foca, Giovanni Messori Ioli, Andrea Ricotti, Oscar Bertetto, Marinella Mistrangelo, Gianni Amunni, Fabrizio Gemmi, Letizia Bachini, Andrea Silenzi, Roberta Pastorino, Andrea Barbara, Andrea Pierini, Ilaria Massa

  31-38

  DOI: https://doi.org/10.33393/abtpn.2019.291

• Emostatic-palliative radiotherapy in vescical carcinoma: two case reports Radioterapia palliativa-emostatica nel carcinoma vescicale: due case reports.

  Giovanni Ceccon, Stefano Andreani, Marialuisa Bergamini, Sebastiano Buti, Cristina Dell'Anna, Francesca Ghetti, Stella Gianni, Claudia Grondelli, Elisabetta Lattanzi, Pierluigi Losardo, Moana Manicone, Roberto Rossi, Francesco Salaroli, Nunziata D'Abbiero

  2 - 4

  DOI: https://doi.org/10.33393/abtpn.2019.111